| Document |
Document Title |
|
WO/2024/154122A1 |
Immune cells expressing a complement receptor are provided. Accordingly, there is provided an immune cell expressing a recombinant protein comprising a transmembrane domain and an extracellular ligand-binding domain of a complement recep...
|
|
WO/2024/153707A1 |
The invention relates to chimeric antigen receptor constructs and their use for treatments and therapies. Further disclosed are methods of treating and/or preventing a disease, such as e.g. a cancer, an infectious disease, an inflammator...
|
|
WO/2024/153005A1 |
The present invention provides a recombinant artemisia vulgaris pollen type III allergen protein Art a3, an encoding gene thereof and an expression and purification method therefor. The amino acid sequence of the protein is shown as SEQ ...
|
|
WO/2024/153722A1 |
The present invention generally relates to immunoconjugates, particularly immunoconjugates comprising a mutant interleukin-2 polypeptide and an antibody that binds to PD-1. In addition, the invention relates to polynucleotide molecules e...
|
|
WO/2024/153938A1 |
The present invention provides a method for modulating the alkaloid content of a plant (e.g. a tobacco plant), the method comprising modifying said plant by modulating the activity or expression of a HNH endonuclease domain containing pe...
|
|
WO/2024/152845A1 |
Provided in the present invention is a recombinant protein vaccine and/or an mRNA vaccine for preventing and/or treating infections of SARS-CoV-2 or a mutant thereof, and particularly provided is a method of using the mRNA vaccine and th...
|
|
WO/2024/155330A1 |
Provided are proteins that bind rare earth metals. The proteins may have enhanced REE/REE selectivity. The proteins may have four EF hand motifs each having 11, 12, or 13 amino acids residues. Each EF hand motif is separated by 12 or 13 ...
|
|
WO/2024/153750A1 |
The present invention relates to substrate molecules suitable for monitoring the enzyme ADAMTS13 via chemiluminescence. The substrates are particularly useful for assaying this enzyme in a sample such as a blood sample.
|
|
WO/2024/154002A1 |
A method for animal protein production in a plant cell is disclosed. The method comprises designing a DNA vector for expression of an animal gene; inserting the DNA vector into the plant cell; grow the cells in defined media under define...
|
|
WO/2024/155798A1 |
Embodiments of the present disclosure pertain to an antibody that binds to GDNF family receptor alpha 2 (GFRA2), where the antibody may be in a modified form that includes, without limitation, a humanized form, a bispecific antibody, a c...
|
|
WO/2024/152259A1 |
The present invention provides a fusion protein having a triple activity and a use thereof. More specifically, the present invention relates to a fusion protein having a triple biological activity of glucagon-like peptide 1 (GLP-1), gluc...
|
|
WO/2024/155457A2 |
Provided herein are HER2 binding proteins, pharmaceutical compositions comprising such proteins or fragments thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such HER2 binding proteins. Also dis...
|
|
WO/2024/153725A1 |
The present invention relates to the combination therapy of recombinant Fc domain - IL-2 variant polypeptides with membrane-anchored antigen binding polypeptides in the prevention or treatment of cancer.
|
|
WO/2024/153006A1 |
Provided in the present invention are a recombinant Artemisia vulgaris pollen type III allergen protein Art v3, an encoding gene thereof, and an expression and purification method therefor. The amino acid sequence of the protein is as sh...
|
|
WO/2024/155905A1 |
The present disclosure relates to Clostridium botulinum neurotoxin serotype A (BoNT/A) compositions with a plurality of 900 kDa Clostridium botulinum neurotoxin serotype A (BoNT/A) complex species. Provided herein are compositions compri...
|
|
WO/2024/152111A1 |
Non-signaling mutant signal regulatory protein alpha (SIRPα) is provided, including a transgene encoding the SIRPα mutant and cells expressing the SIRPα mutant. Non-signaling mutant SIRPα is modified such that the signaling that resu...
|
|
WO/2024/154145A1 |
Nucleic acid molecules comprising a first sequence encoding a cyclic nucleotide gated potassium channel or a functional fragment thereof and a second sequence encoding a chemogenetically activatable cyclic adenosine monophosphate (cAMP) ...
|
|
WO/2024/153075A1 |
A capsid protein variant, recombinant AAV virus particles comprising same, and a method for using the recombinant AAV virus particles to treat an ocular disease. The capsid protein variant comprises the following amino acid mutation site...
|
|
WO/2024/153793A1 |
The present disclosure relates to a nucleic acid molecule comprising 5'-UTR and/or 3'-UTR sequences that yield high translation levels. Aspects of the disclosure further relate to nucleic acid molecules suitable for use as a vaccine in t...
|
|
WO/2024/155160A1 |
The present invention relates to: GFRAL-specific antisense oligomers targeting the GDNF family receptor alpha like (GFRAL) gene; and a pharmaceutical composition for preventing or treating obesity, diabetes, appetite loss, or cachexia, t...
|
|
WO/2024/153172A1 |
A construct specifically binding to MSLN, an engineered stem cell and engineered immune cell comprising same, and the use thereof in preparation of a drug, the drug being used for preventing and/or treating tumors in subjects. The presen...
|
|
WO/2024/155907A2 |
Disclosed are immunogens for stimulating an immune response to coronaviruses. The immunogens can be non-receptor binding domain (RED) epitopes. The immunogens can be grafted into a scaffold polypeptide to produce an epitope scaffold. Ant...
|
|
WO/2024/155561A2 |
The present invention provides engineered soluble F proteins of paramyxoviruses such as respiratory syncytial viruses (RSVs), human metapneumoviruses (hMPVs), and human parainfluenza viruses (hPIVs). These engineered proteins are stabili...
|
|
WO/2024/155094A1 |
The present invention relates to an epitope of leucine-rich and immunoglobulin-like domains 1 (Lrig-1) protein, which is an antigen present on the surface of a regulatory T cell or an adipocyte, and to an antibody or an antigen-binding f...
|
|
WO/2024/155683A1 |
Compositions and methods for treating or reducing the severity or likelihood of occurrence of a parasitic worm infection in a humans and domestic animals are described. The compositions include inactivated recombinant bacteria expressing...
|
|
WO/2024/155630A2 |
The invention provides methods and materials for the preparation of immune cells, including T cells engineered to express exogenous T cell receptors that target polypeptides associated with human leukocyte antigens. Embodiments of the in...
|
|
WO/2024/155027A1 |
The present invention relates to an attenuated Salmonella gallinarum expressing FliC or FliC-hiL2 and use thereof. The Salmonella strain according to the present invention has excellent immune activity and exhibits excellent anti-cancer ...
|
|
WO/2024/152112A1 |
G protein-coupled receptor (GPCR) antibodies coupled to an HD peptide are disclosed, as well as methods of manufacture and uses of said antibodies. The HD peptides may comprise (i) an amino acid sequence of a naturally occurring HD pepti...
|
|
WO/2024/155124A1 |
The present invention relates to a protein which is recombined on the basis of the Milk fat globule-EGF factor 8 (MFG-E8) protein, comprises an amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 3, and can be expected to prevent or treat ...
|
|
WO/2024/154138A1 |
The present invention relates to a chimeric polypeptide for use in in-vitro tissue engineering, the chimeric polypeptide comprising a cellulose binding domain (CBD); at least one extracellular matrix (ECM) module; and optionally at least...
|
|
WO/2024/152113A1 |
Antibodies or antigen binding fragments against infectious diseases having a homologous dimerization (HD) peptide coupled thereto are disclosed, as well as methods of manufacture and uses thereof. The HD peptides may comprise (i) an amin...
|
|
WO/2024/152996A1 |
A messenger ribonucleic acid (mRNA) molecule, comprising: an expression cassette 1 containing a coding sequence of RNA replicase, and an expression cassette 2 containing a coding sequence of an antigen. Further provided are a mRNA vaccin...
|
|
WO/2024/153091A1 |
The present invention provides a series of polypeptides containing a modified structure. The series of polypeptides act on three targets, i.e., GLP-1, GIP and GCG, and has prospects of being developed into drugs for the prevention or tre...
|
|
WO/2024/153090A1 |
The present invention provides a series of polypeptide compounds and pharmaceutically acceptable salts thereof. The series of polypeptides act on three targets including GLP-1, GIP, and GCG, and have the prospect of development into drug...
|
|
WO/2024/153235A1 |
The present invention provides fusion proteins of gE and gI (or variants thereof) that can be used for preventing or treating varicella-zoster virus infection, and use of such fusion proteins (or the variants thereof).
|
|
WO/2024/152998A1 |
Use of a CpG adjuvant in the preparation of a novel coronavirus vaccine. Provided is a composite adjuvant, comprising the CpG adjuvant and an A1 adjuvant. The nucleotide sequence of the CpG adjuvant is SEQ ID NOs: 1-5. Provided is a nove...
|
|
WO/2024/153764A1 |
The present invention relates to recombinant variants of R-spondin proteins and their use as a medicament, in particular for the treatment of diabetes.
|
|
WO/2024/153768A1 |
This invention relates to IL-12 Fc fusion proteins and their use in medicine, pharmaceutical compositions comprising the same, and methods of using the same as agents for treatment and/or prevention of cancer.
|
|
WO/2024/155787A2 |
The present invention relates to the phosphatidylserine (PS) binding compound derivative and the fusion of PS binding compound with an arm compound. The present invention describes the methods of producing and using PS binding compound d...
|
|
WO/2024/155750A1 |
The present disclosure provides bifunctional molecules including a moiety that targets a lysosomal targeting molecule, a linker, and a polypeptide that specifically binds a extracellular target molecule such as an antibody that is target...
|
|
WO/2024/153619A1 |
The invention relates to isolated protein comprising a histone H1 globular (H1g) domain, and methods and uses thereof. The invention may be used to detect and isolate circulating, cell free nucleosomes, in particular nucleosomes of disea...
|
|
WO/2024/153794A1 |
The present disclosure relates to methods of inducing a pan-sarbecoronavirus variant immune response for the treatment and prevention of coronavirus infections.
|
|
WO/2024/155900A2 |
Provided herein are compositions comprising a Clostridium botulinum neurotoxin serotype A (BoNT/A) complex comprising a 150 kDa BoNT/A. Said 150 kDa BoNT/A is in the form of a plurality of sequence variant species, wherein the plurality ...
|
|
WO/2024/155287A1 |
A printer system is provided for fabricating three-dimensional structures from biomaterial. The printer system comprises a housing, an arm assembly, a printing surface, and an extruding system. The arm assembly is coupled to the housing....
|
|
WO/2024/153120A1 |
The present invention relates to a mutated PD1 ectodomain fragment and a CAR containing same, and an NK cell. Specifically, the present invention provides a polypeptide, which is the mutated PD1 ectodomain fragment containing an amino ac...
|
|
WO/2024/153183A1 |
Provided are interleukin 18 (IL-18) variant polypeptides having at least one mutation at a residue selected from the group consisting of: C38, C68, C76, S117, and C127, wherein the amino acid position is relative to a wild-type human IL-...
|
|
WO/2024/155553A1 |
The present disclosure relates to peptide inhibitors of the interleukin-23 receptor (IL-23R) or pharmaceutically acceptable salts thereof, corresponding pharmaceutical compositions, methods and/or uses for treatment of autoimmune inflamm...
|
|
WO/2024/155583A1 |
The present application is directed to methods for producing a population of cells comprising y5 T cells. The present application is also directed to, e.g, compositions useful for such production methods, populations of produced cells, a...
|
|
WO/2024/155631A1 |
The ability to selectively bind to antigenic peptides and secrete cytokines and other biomolecules can define T cells with therapeutic potential in T cell receptor (TCR) immunotherapies. Hydrogel microparticles (nanovials) having cavitie...
|
|
WO/2024/152432A1 |
A dual-gate pore protein, a pore protein mutant, a nucleotide sequence, and the use thereof, belonging to the technical field of nanopore single-molecule detection. The amino acid sequence of the dual-gate pore protein is as shown in SEQ...
|
